nevirapine has been researched along with Sarcoma, Kaposi in 8 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Sarcoma, Kaposi: A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| " As of September 1, 1996, ADAP began covering HIV protease inhibitors, viral load evaluations, and other crucial anti-HIV and opportunistic infection agents, including nevirapine for HIV, cidofovir for CMV, and DaunoXome for Kaposi's sarcoma." | 3.69 | New York ADAP to cover new AIDS drugs plus viral load testing. ( Link, D, 1996) |
| "The optimal approach to HIV-associated Kaposi sarcoma (HIV-KS) in sub-Saharan Africa is unknown." | 2.77 | A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. ( Aboobaker, J; Coovadia, HM; Esterhuizen, T; Friedland, GH; Mosam, A; Scadden, DT; Shaik, F; Uldrick, TS, 2012) |
| "HIV-associated Kaposi sarcoma (HIV-KS) is the most common cancer in Malawi." | 1.42 | Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi. ( Bazile, J; Beste, JA; Chingoli, F; Crocker, JT; Elmore, SN; Gopal, S; Herce, ME; Kalanga, N; Keck, JW; Mailosi, B; Phiri, A; Rigodon, J; Tengatenga, L; Wroe, EB, 2015) |
| "A retrospective cohort of 124 AIDS patients initiating ART under routine practice conditions was studied." | 1.39 | AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe. ( Borok, MZ; Campbell, TB; Makadzange, AT; Mhlanga, TO; Nelson, BC, 2013) |
| "We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction." | 1.33 | No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. ( Beijnen, JH; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Schellens, JH, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nelson, BC | 1 |
| Borok, MZ | 1 |
| Mhlanga, TO | 1 |
| Makadzange, AT | 1 |
| Campbell, TB | 1 |
| Herce, ME | 1 |
| Kalanga, N | 1 |
| Wroe, EB | 1 |
| Keck, JW | 1 |
| Chingoli, F | 1 |
| Tengatenga, L | 1 |
| Gopal, S | 1 |
| Phiri, A | 1 |
| Mailosi, B | 1 |
| Bazile, J | 1 |
| Beste, JA | 1 |
| Elmore, SN | 1 |
| Crocker, JT | 1 |
| Rigodon, J | 1 |
| Mosam, A | 1 |
| Shaik, F | 1 |
| Uldrick, TS | 1 |
| Esterhuizen, T | 1 |
| Friedland, GH | 1 |
| Scadden, DT | 1 |
| Aboobaker, J | 1 |
| Coovadia, HM | 1 |
| Kappelhoff, BS | 1 |
| Huitema, AD | 1 |
| Mairuhu, AT | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Erlander, SR | 1 |
| Shaw, AJ | 1 |
| McLean, KA | 1 |
| Link, D | 1 |
1 trial available for nevirapine and Sarcoma, Kaposi
| Article | Year |
|---|---|
A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.
Topics: Adult; Anti-HIV Agents; Antigens, Neoplasm; Antiretroviral Therapy, Highly Active; Drug Therapy; Fem | 2012 |
7 other studies available for nevirapine and Sarcoma, Kaposi
| Article | Year |
|---|---|
AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Coinfection; Drug Therapy, Combination; | 2013 |
Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.
Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Nevirapine; Retrosp | 2015 |
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Cytochrome P-450 | 2005 |
The eighth mystery of acquired immune deficiency syndrome and the "Trojan horse' mechanism.
Topics: Acquired Immunodeficiency Syndrome; Apoptosis; CD4-Positive T-Lymphocytes; Endopeptidases; Eosinophi | 1996 |
Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Male; Nevirapine; Reverse | 1999 |
New York ADAP to cover new AIDS drugs plus viral load testing.
Topics: Acquired Immunodeficiency Syndrome; Antibiotics, Antineoplastic; Antiviral Agents; Cytomegalovirus I | 1996 |
FDA news. Food and Drug Administration.
Topics: Antineoplastic Agents; Child; Dermatologic Agents; Drug Approval; HIV Infections; Humans; Nevirapine | 1999 |